BMRN
BioMarin Pharmaceutical Inc.
92.35
USD
This page is just a preview of the data found in TrendSpider’s full version
BioMarin Pharmaceutical Inc. stock is up 15.92% since 30 days ago. The next earnings date is Feb 26, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 64% of the previous 24 December’s closed higher than November. In the last 10 Unusual Options Trades, there were 6 CALLs, 4 PUTs. 50% of analysts rate it a buy.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 16 Nov 15:55 | 19 Apr, 2024 | 100.00 | 1563 | ||
| 16 Nov 15:56 | 19 Apr, 2024 | 100.00 | 1563 | ||
| 16 Nov 17:19 | 19 Apr, 2024 | 100.00 | 1563 | ||
| 17 Nov 20:44 | 17 Nov, 2023 | 90.00 | 430 | ||
| 17 Nov 20:51 | 17 Nov, 2023 | 90.00 | 430 | ||
| 20 Nov 18:15 | 19 Jan, 2024 | 85.00 | 257 | ||
| 20 Nov 19:28 | 19 Jan, 2024 | 85.00 | 257 | ||
| 30 Nov 16:06 | 19 Jan, 2024 | 90.00 | 1743 | ||
| 30 Nov 18:27 | 19 Apr, 2024 | 100.00 | 488 | ||
| 30 Nov 18:27 | 19 Apr, 2024 | 100.00 | 488 |
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.
